Searched for
INHALATION ANESTHESIA
In 1844, Horace Wells watched a laughing-gas stunt hide pain in plain sight, and it wasn’t just a party trick: It changed anesthesiaPicture the year 1844: a dentist named Horace Wells observes a surreal scene where a man inhaling nitrous oxide, famed for inducing laughte...- Possibility and probability favour them in war and peace: 10 large-cap stocks from 2 sectors with upside potential of up to 28%Probability theory is important in the stock market. Reason: Stock prices are a function of many factors and the underlying operating matri...
- Piramal Pharma Q3 Results: Co reports loss as CDMO slowdown drags revenuePiramal Pharma swung to a Rs 136 crore Q3 loss as revenue fell 3%, hit by CDMO destocking, weak US biopharma funding, trade uncertainty and...
- For medium- to long-term investors: 8 large- & mid-cap stocks from different sectors with an upside potential of up to 49%Today’s selection of stocks, though from different sectors, have created wealth over the years. Now, such stocks have some things in common...
- For investors seeing bearish phase for the first time: 6 stocks from different sectors with upside potential of up to 51%While the current market correction has been underway for six months, the last two weeks have been particularly painful. With extremely poo...
- For medium- and long-term investors focused on wealth creation: 8 large-cap stocks with an upside potential of up to 51%In all the companies on our list today, there are reasons to buy that have to be seen independent of the volatility on the street. The prob...
- Piramal Pharma posts Rs 4 crore net profit in Q3FY25Piramal Pharma on Tuesday reported net profit of Rs 4 crore in Q3FY25.
- Piramal Pharma shares soar 15% after reporting 4-fold jump in Q2 profitPiramal Pharma Share Price: The company's revenue from operations increased to Rs 2,242 crore in the second quarter, up 17% year-on-year fr...
- Piramal Pharma Q2 Results: Net profit jumps over 4-fold to Rs 23 cr; revenue at Rs 2,242 crPiramal Pharma reported a significant increase in consolidated net profit for Q2, growing from Rs 5 crore last year to Rs 23 crore. Revenue...
- Piramal Pharma Q2 Results: Co posts net profit of Rs 23 croreThe contract research and manufacturing services (CDMO) revenues rose 24% YoY to Rs 1324 crore led by order inflow momentum, especially for...
- What drives the sector is key to long term investments: 5 large cap stocks from different sectors with upside potential up to 19%There are some sectors where the macro structure is such that for one or the other reasons the overall growth is higher. This is not to say...
- Supriya Lifescience expects to double revenue to Rs 1,000 crore in next 3 yearsSupriya Lifescience aims to double revenue to Rs 1,000 crore by venturing into higher-margin niche segments. Led by Satish Wagh, it is expa...
- Fundamental Radar: Why does Piramal Pharma stock deserve a re-rating? Sandeep Raina explainsThe company witnessed multiple challenges related to macroeconomic factors during and after COVID-19, high attrition at European manufactur...
- Piramal Pharma posts Rs 10 crore net profit in Q3FY24Piramal Pharma Q3 Results: Revenue from operations rose 14% YoY driven by double digit growth across all the three businesses.
- Piramal Pharma Q4 Results: Net profit slides 75% YoY to Rs 50 croreOn like-to-like financials, the CDMO business that contributes 57% of revenues, declined 8% YoY to Rs 2164 crore. The complex hospital gene...
- Piramal Pharma Q2 Results: Piramal Pharma post net loss of Rs 37 crore in Q2FY23The complex hospital generic business that contributes one-third of revenues grew 12% YoY to Rs 562 crore. Piramal said it is witnessing st...
- Piramal Enterprises to buy 5 Janssen drugs for Rs 1,164 croreThe transaction, which is expected to close this week, marks the Ajay Piramal-led company’s sixth deal in the healthcare space in the past ...
- Open for acquisitions especially in OTC space: Nandini Piramal, Piramal EnterprisesThe deal allow us to leverage our distribution and our marketing network in over 50 countries, said Nandini Piramal.
- Piramal to buy select injectable brands from Janssen for up to $175 millionPiramal will pay an upfront cash of $155 million and the rest on meeting certain sales-related milestones, a press release said.
- Piramal Enterprises likely to hive off its critical care businessThe key driver is the valuation and if it does not match expectations, the deal may not move quickly,” an industry source, who claimed know...
Load More
